CN103356581A - Application of Sarcaboside A in preparation of drug for treating liver cancer - Google Patents
Application of Sarcaboside A in preparation of drug for treating liver cancer Download PDFInfo
- Publication number
- CN103356581A CN103356581A CN 201310265268 CN201310265268A CN103356581A CN 103356581 A CN103356581 A CN 103356581A CN 201310265268 CN201310265268 CN 201310265268 CN 201310265268 A CN201310265268 A CN 201310265268A CN 103356581 A CN103356581 A CN 103356581A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- drug
- liver cancer
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses application of Sarcaboside A in preparation of a drug for treating liver cancer, which belongs to the technical field of new applications of drug. According to the invention, the in-vitro MTT (Methyl Thiazolyl Tetrazolium) antitumor activity evaluation discovers that Sarcaboside A also has an obvious inhibiting effect on the growth of human liver cancer cell strains HepG2, MHCC-LM3, Bel-7402 and HuH-7. Thus, Sarcaboside A can be used for preparing an anti-liver lung cancer drug and has good development and application prospects. The application of Sarcaboside A in preparation of the drug for treating liver cancer is disclosed for the first time. The skeleton type is brand new and Sarcaboside A has unexpectedly high inhibitory activity on liver cancer cell.
Description
Technical field
The present invention relates to the new purposes of compound S arcaboside A, relate in particular to the application of Sarcaboside A in the preparation medicines resistant to liver cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound S arcaboside A that the present invention relates to is one and delivered (Li in 2012, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.) New skeleton compound, this chemical compound has brand-new framework types, there is not at present the report about activity, belong to open first for the purposes in preparation Hepatoma therapy medicine that the present invention relates to, and because framework types belongs to brand-new framework types, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously hepatocarcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compound S arcaboside A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Sarcaboside A in the preparation medicines resistant to liver cancer, and the structural formula of Sarcaboside A is shown in formula I:
Formula I
The present invention finds that by external MTT anti-tumor activity evaluation Sarcaboside A also has significant inhibitory action to the growth of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 8.13 ± 0.45 μ M, 7.79 ± 0.459 μ M, 6.28 ± 0.38 μ M and 10.36 ± 1.11 μ M.Therefore, Sarcaboside A can for the preparation of medicines resistant to liver cancer, have good development prospect.
The present invention relates to the purposes of Sarcaboside A in preparation Hepatoma therapy medicine and belong to open first, because framework types belongs to brand-new framework types, and its inhibition for hepatoma carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously hepatocarcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound S arcaboside A involved in the present invention is referring to document (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound S arcaboside A tablet involved in the present invention:
Get 20 and digest compound Sarcaboside A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound S arcaboside A capsule involved in the present invention:
Get 20 and digest compound Sarcaboside A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Sarcaboside A to the growth inhibited effect of human hepatoma cell strain
1. method: the cell that is in the growth logarithmic (log) phase: HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Sarcaboside A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Sarcaboside A has significant inhibitory action to the growth of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7.This chemical compound suppresses the IC of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7 growth
50Value is respectively: 8.13 ± 0.45 μ M, 7.79 ± 0.459 μ M, 6.28 ± 0.38 μ M and 10.36 ± 1.11 μ M.
Shown that by above-described embodiment Sarcaboside A of the present invention has good inhibitory action to the growth of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7.Prove that thus Sarcaboside A of the present invention has resisting liver cancer activity, can be for the preparation of medicines resistant to liver cancer.
Claims (1)
1.Sarcaboside the application of A in the Hepatoma therapy medicine, described compound S arcaboside A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310265268 CN103356581A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A in preparation of drug for treating liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310265268 CN103356581A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A in preparation of drug for treating liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356581A true CN103356581A (en) | 2013-10-23 |
Family
ID=49359403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310265268 Pending CN103356581A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside A in preparation of drug for treating liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356581A (en) |
-
2013
- 2013-06-27 CN CN 201310265268 patent/CN103356581A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872069B (en) | Application of Houttuynoid C to preparing drugs for treating liver cancer | |
| CN102872141B (en) | Application of Houttuynoid E in drug for treating liver cancer | |
| CN103120678A (en) | Application of Aphanamixoid A in medicine for treating liver cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861089B (en) | Application of Houttuynoid B in medicine for treating liver cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN103356581A (en) | Application of Sarcaboside A in preparation of drug for treating liver cancer | |
| CN103356557A (en) | Application of Sarcaboside B in preparation of medicines for treating liver cancer | |
| CN103356545A (en) | Application of Sarcaboside B in medicine used for treating ovarian cancer | |
| CN103356560A (en) | Application of Sarcaboside B in medicine used for treating prostate cancer | |
| CN103356550A (en) | Application of Sarcaboside B in medicine used for treating laryngeal cancer | |
| CN103371996A (en) | Application of Sarcaboside A in medicine for treating nasopharynx cancer | |
| CN103356534A (en) | Application of Sarcaboside B in medicine used for treating colorectal cancer | |
| CN102872116A (en) | Application of Houttuynoid D in medicament for treating liver cancer | |
| CN103446130A (en) | Application of Lycojaponicumin B in liver cancer treatment drug | |
| CN103356538A (en) | Application of Sarcaboside A in preparation of drug for treating ovarian cancer | |
| CN103356541A (en) | Application of Sarcaboside B in medicine used for treating gastric cancer | |
| CN103356553A (en) | Application of Sarcaboside A in preparation of drug for treating breast cancer | |
| CN103462959A (en) | Application of Incarviatone A in medicaments for treating liver cancer | |
| CN103356561A (en) | Application of Sarcaboside B in medicine used for treating renal cancer | |
| CN103356535A (en) | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer | |
| CN103356577A (en) | Application of Sarcaboside A in preparation of drug for treating stomach cancer | |
| CN103356532A (en) | Application of Sarcaboside B in medicine used for treating breast cancer | |
| CN103446150A (en) | Application of Lycojaponicumin C in liver cancer treatment drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |